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Hepatic veno-occlusive disease (VOD) is a serious complication of high-dose chemotherapy regimens, such as
those used in hematopoietic cell transplantation recipients. Deﬁbrotide is considered a safe and effective
treatment when dosed at 25 mg/kg/day. However, patients who develop VOD still have increased mortality
despite the use of deﬁbrotide. Data are limited on the use of doses above 60 mg/kg/day for persistent VOD. In
this prospective clinical trial 34 patients received escalating doses of deﬁbrotide. For patients with persistent
VOD despite doses of 60 mg/kg/day, doses were increased to a maximum of 110 mg/kg/day. Increased toxicity
was not observed until doses rose beyond 100 mg/kg/day. Patients receiving doses between 10 and 100 mg/
kg/day experienced an average of 3 bleeding episodes per 100 days of treatment, whereas those receiving
doses >100 mg/kg/day experienced 13.2 bleeding episodes per 100 days (P ¼ .008). Moreover, dose re-
ductions due to toxicity were needed at doses of 110 mg/kg/day more often than at lower doses. Deﬁbrotide
may be safely escalated to doses well above the current standard without an increase in bleeding risk.
However, the efﬁcacy of this dose-escalation strategy remains unclear, because outcomes were similar to
published cohorts of patients receiving standard doses of deﬁbrotide for VOD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION Therapies for VOD are mostly supportive, with diuretics
Hepatic veno-occlusive disease (VOD) or sinusoidal
obstruction syndrome may occur after high-dose chemo-
therapy regimens, like those used in hematopoietic cell
transplantation (HCT), and severe cases are associated with a
poor prognosis [1]. VOD is the result of sinusoidal endothelial
cell damage in the liver and occurs in up to 12% of autologous
and 40% of allogeneic HCT [2]. Additionally, plasminogen
activator inhibitor-1 is recognized as a main contributor to
the pathogenesis of VOD by preventing ﬁbrinolysis by tissue
plasminogen activator, thereby promoting clot formation
[3,4]. This ultimately leads to sinusoidal obstruction, hepatic
veno-occlusion, severe portal hypertension, and diminished
liver function [5]. Classical signs and symptoms include he-
patomegaly, right upper quadrant abdominal pain, hyper-
bilirubinemia, refractory thrombocytopenia, ascites, and
weight gain [6,7].edgments on page 2152.
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ty for Blood and Marrow Transplantation.and ﬂuid restriction. Many patients with VOD are able to
recover fully with supportive care. In retrospective studies
these cases are deﬁned as mild or moderate VOD, whereas
those who died or with persistent VOD for longer than
100 days are classiﬁed as severe VOD [8,9]. Clinically, severe
cases manifest as progressive hepatorenal syndrome and
multiorgan failure (MOF) and carry a 100-day mortality
rate in excess of 75% [2,8,10]. Systemic anticoagulants
and thrombolytic therapies carry substantial risk of
life-threatening hemorrhage [11,12].
Deﬁbrotide, initially named fraction P because of its
phosphate-rich content, is a low-molecular-weight, single-
stranded DNA adenosine receptor agonist that has ﬁbrinolytic,
antithrombotic, and anti-ischemic properties [12,13]. It selec-
tively binds to damaged endothelium and up-regulates the
release of prostacyclin, prostaglandin E2, thrombomodulin,
and tissue plasminogen activator [5]. Deﬁbrotide may also
decrease plasma levels of plasminogen activator inhibitor-1,
allowing ﬁbrinolysis [14]. The resulting vasodilation and clot
breakdown reverses the pathophysiology of VOD. Deﬁbrotide
has also been shown to be a safer alternative to therapeutic
heparin, antithrombin, or tissue plasminogen activator [15]
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VOD and MOF in at least 1 series [16].
Although deﬁbrotide is generally considered to be an
effective treatment, themortality rate in patients with severe
VOD remains high. With deﬁbrotide treatment, complete
response rates of 36% to 76% and 100-day survival rates of 32%
to 64% have been observed in various populations with VOD
[12,13,17-19]. Therefore, further optimization of VOD therapy
is needed. In the studies published to date deﬁbrotide has
been dosed from 25 mg/kg/day to a maximum of 60 mg/kg/
day [13,16,17,20,21]. One study found that the average deﬁb-
rotide dose in responders was signiﬁcantly higher than in
nonresponders [22].More recently, however, Richardsonet al.
[12] performed a randomized trial demonstrating no signiﬁ-
cant differences between complete response rates, 100-day
survival, or toxicity in patients receiving 25 mg/kg/day
versus 40 mg/kg/day. Deﬁbrotide has been dosed as high as
110 mg/kg/day in 1 patient, with complete resolution of VOD
without hemorrhage or toxicity [22].
It remains unclear if treatment of severe VOD at doses
above 60 mg/kg/day is safe and effective. The purpose of this
study was to evaluate the safety and efﬁcacy of deﬁbrotide
escalated up to 110 mg/kg/day in patients with persistent
VOD at 60 mg/kg/day.
METHODS
Patient Selection
This single-center, prospective study received institutional review board
approval and was performed at St. Jude Children’s Research Hospital be-
tween January 2004 and September 2009 (clinicaltrials.gov identiﬁer:
NCT00143546). All participants (or respective legal guardians) gave written
informed consent. Deﬁbrotide was available under US Food and Drug
Administrationeapproved Investigational New Drug application 68012.
Patients were eligible if they met diagnostic criteria for VOD, using
either (1) Jones criteria, which are hyperbilirubinemia (2 mg/dL) and 2 of
the following conditions: hepatomegaly, ascites, or weight gain (5% of
baseline); or (2) McDonald criteria, which are at least 2 of the following by
day þ20: hepatomegaly or right upper quadrant pain, jaundice or hyper-
bilirubinemia (2 mg/dL), and ascites or sudden weight gain (>2% of
baseline). Patients were excluded if observed symptoms could be attribut-
able to a diagnosis other than VOD.
Laboratory and Clinical Evaluation
Monitoring during deﬁbrotide therapy included daily physical exami-
nation, weekly abdominal ultrasound with liver Doppler measurement, and
complete blood counts and chemistry panels at least 4 times aweek. Data on
weight gain, presence of right upper quadrant abdominal pain, hepato-
megaly, and ﬂuid retention were collected for each patient. Coagulation
parameters (antithrombin III [ATIII], prothrombin time [PT], patial throm-
boplastin time [PTT], ﬁbrinogen, and D-dimer) were measured at least
weekly. Follow-up evaluations continued to day 14 after administration of
the last dose of deﬁbrotide. On completion of therapy a physical examina-
tion to document weight, liver size, and right upper quadrant abdominal
tenderness was conducted. Onset of VOD was deﬁned as the ﬁrst day a
patient met VOD criteria. Day 0was deﬁned as the date of cellular infusion in
patients receiving HCT or the ﬁrst day of the last chemotherapy cycle.
Renal insufﬁciency was deﬁned as creatinine 3 times baseline, renal
failure as receiving dialysis, pulmonary insufﬁciency as the need for sup-
plemental oxygen for >24 hours, and pulmonary failure as receiving me-
chanical ventilation. Mild MOF was deﬁned as VOD coexisting with either
pulmonary or renal insufﬁciency. Severe MOF was deﬁned as VOD in the
presence of pulmonary or renal failure.
Treatment Design
Deﬁbrotide was administered to patients intravenously in 1 of 2 dosing
regimens. From 2003 to August 2006 patients were dosed at 10 mg/kg/day,
divided every 6 hours, then escalated by 10 mg/kg/day, and plateaued at
60 mg/kg/day by day 6. A rapid escalation regimenwas adopted starting late
2006; the initial dose was 6.25 mg/kg, the second dose was 7.5 mg/kg, the
third dosewas 10mg/kg, the fourth dosewas 12.5mg/kg (total 36.25mg/kg/
day), and then the dose plateaued on the second day at 15 mg/kg/dose
(60 mg/kg/day). In patients with rapidly progressing VOD, doses were
allowed to be escalated faster at the discretion of the clinician. For patients
with persistent VOD at 60 mg/kg/day, further escalation was allowed atincrements of 10 mg/kg/day to a maximum of 110 mg/kg/day or until
toxicity attributable to deﬁbrotide was noted. Dosing was based on baseline
weight, obtained before the start of transplant or chemotherapy. Therapy
was continued until patients improved. Transfusions were used to keep
platelets20 109/L and hematocrit30%, with clotting factors replaced as
needed. Complete response was deﬁned as evidence of complete resolution
of VOD-related symptoms and a decrease in bilirubin to 2 mg/dL.
Adverse Events
All patients weremonitored for the development of adverse events from
the time of administration of the ﬁrst dose of deﬁbrotide until 14 days after
the last dose, which were recorded according to the National Cancer In-
stitute’s Common Terminology Criteria for Adverse Events v3.0. If signiﬁcant
toxicity attributable to deﬁbrotide occurred, it was reduced by 50% or dis-
continued if the symptoms were life-threatening.
Statistical Analysis
Fisher exact test was used to compare the difference of 2 proportions of
bleeding and hypotension events. The Kaplan-Meier method was used for
overall survival (OS) estimates. OS was deﬁned as the time from start of
deﬁbrotide treatment until death from any cause. Cumulative incidence of
nonrelapse mortality (NRM) was deﬁned from the start of deﬁbrotide
treatment until death due to treatment, with relapse as a competing risk.
Univariate Cox proportional regression, Poisson regression, and Fine and
Gray’s regression analysis were used to test associations between factors
and OS, bleeding events, and NRM, respectively [23,24]. Factors analyzed
were time from transplant/chemotherapy to onset of VOD, bilirubin level at
the time of VOD diagnosis, peak bilirubin level, receipt of dialysis, receipt of
mechanical ventilation, and peak dose of deﬁbrotide. All surviving partici-
pants were censored at the time of last follow-up date. All reported P values
are 2-sided and are considered statistically signiﬁcant at <.05. Statistical
analyses were performed with R-3.1.0 [25].
RESULTS
Patient Characteristics
Thirty-ﬁve consecutive patients who received deﬁbrotide
were evaluated. One patient who received deﬁbrotide for
pulmonary VODwas excluded, leaving 34 patients in the ﬁnal
analysis (Table 1). Thirty-one patients developed VOD after
transplantation, and 3 had received chemotherapy without
transplantation.Themedianagewas8years,11months (range,
.5 to 21.6 years). Most patients (74%) had a hematologic ma-
lignancy. Twelve patients received total body irradiation, 10
patients received busulfan, 18 patients received cyclophos-
phamide, and 14 received melphalan in their preparative
regimen. All 3 nontransplant patients had acute leukemia.
Before developing VOD, 1 patient had received clofarabine,
etoposide, and cyclophosphamide; 1 had receivedﬂudarabine,
cytarabine, Mylotarg, and granulocyte colony-stimulating
factor; and the third patient had received dexamethasone,
etoposide, and cyclophosphamide. All transplant patients
received continuous infusion of heparin for VOD prophylaxis.
Characterization of VOD and MOF
VOD developed at a median of 12 days after transplant/
chemotherapy (range, 7 to 78). The median bilirubin level
at the time of VOD diagnosis was 4.5 mg/dL (range, 2 to 19.7).
Nineteen patients (56%) had MOF at enrollment, with
another 10 patients developing MOF while on deﬁbrotide
treatment (5 within 1 day). Ultimately, MOF occurred in 29
patients (85%), with most (n ¼ 22) being severe. Twenty-six
patients had renal insufﬁciency; 17 received dialysis. Pul-
monary insufﬁciency was documented in 29 patients; 20
received mechanical ventilation.
Deﬁbrotide Administration
Themedian time fromVODdiagnosis to start of deﬁbrotide
therapy was 0 days (range, 0 to 6), with 30 patients (88%)
startingdeﬁbrotidewithin1dayofVODdiagnosis. Themedian
peak deﬁbrotide dose was 60 mg/kg/day (range, 6.25 to 110).
Table 1
Patient Characteristics (N ¼ 34)
Characteristic Value
Age, yr
0-6 12 (35%)
6-12 6 (18%)
12-18 13 (38%)
>18 3 (9%)
Sex
Male 25 (74%)
Female 9 (26%)
Disease
Acute myeloid leukemia 10 (29%)
Acute lymphoid leukemia 10 (29%)
Other hematologic malignancy (CML, NHL, JMML) 5 (15%)
Nonhematologic malignancy (Wilms, NB) 5 (15%)
Nonmalignant (PNH, I-Cell, SAA, OP) 4 (12%)
HCT number
1 23 (68%)
>1 8 (24%)
No HCT 3 (9%)
Donor type
Autologous 2 (6%)
Allogeneic 29 (94%)
Matched related ¼ 4
Matched unrelated ¼ 13
Mismatched related ¼ 12
Graft type
Peripheral blood 14 (41%)
Bone marrow 15 (44%)
Umbilical cord blood 2 (6%)
Conditioning regimens
Total body irradiation/cyclophosphamide 10 (32%)
Fludarabine/melphalan (cyclophosphamide) 7 (23%)
Busulfan/melphalan 6 (19%)
Busulfan/cyclophosphamide 4 (13%)
Fludarabine/total body irradiation 2 (6%)
Cyclophosphamide þ other 2 (6%)
VOD prophylaxis
Heparin 30 (97%)
Heparin þ ursodiol 1 (3%)
MOF severity
No MOF 5 (15%)
Mild 7 (21%)
Severe 22 (64%)
Systems as part of MOF (liver þ renal þ pulmonary)
Renal þ pulmonary 26 (76%)
Pulmonary only 3 (9%)
CML indicates chronic myeloid leukemia; NHL, non-Hodgkin lymphoma;
JMML, juvenile myelomonocytic leukemia; NB, neuroblastoma; PNH,
paroxysmal nocturnal hemoglobinuria; SAA, severe aplastic anemia; OP,
osteopetrosis.
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(range, 1 to 102). Eleven patients (32%) received a dose esca-
lationabove60mg/kg/day (Table2). In thesepatients amedian
of 1 day was spent at 60 mg/kg/day (range, 0 to 34). Three
patientswere escalated to amaximumdose of 70mg/kg/day,1
patient to 80mg/kg/day,1 patient to 90mg/kg/day,1 patient to
100mg/kg/day, and 5 patients to 110mg/kg/day. Therewas no
difference in the incidence of MOF in those who did or did not
receive deﬁbrotide doses >60 mg/kg/day. The median total
bilirubin level at diagnosis was 4.5 mg/dL in patients who
received a maximum deﬁbrotide dose >60 mg/kg/day and
4.3mg/dL inpatientswho never received deﬁbrotide in excess
of 60 mg/kg/day. Reasons for stopping deﬁbrotide included
death (10 patients, 29.4%), resolution of VOD (19 patients,
55.9%), VOD progression (4 patients, 11.8%), and transition to
palliative care (1 patient, 2.9%).
Toxicity and Dosage Reduction
Thirteen patients experienced a total of 25 bleeding
events. Grade 3 bleeding events occurred 23 times, whereasgrade 4 bleeding events occurred twice. Bleeding was not a
primary cause of death in any patient. Table 3 details the
number of bleeding events that occurred at various deﬁb-
rotide doses. The incidence of a bleeding event at doses of
deﬁbrotide between 0 and 100 mg/kg/day was 3 per 100
patient-days, and the incidence of a bleeding event at doses
of deﬁbrotide>100mg/kg/daywas 13.2 per 100 patient-days
(Fisher’s exact test P ¼ .008, Table 3). In total, 4 of 5 patients
who were receiving 110 mg/kg/day dosing required a 50%
dose reduction, primarily because of bleeding. Most bleeding
events were not associated with severely abnormal labora-
tory coagulation parameters, because only 6 bleeding events
occurred with platelet counts < 20,000/mm3, International
Normalized Ratio > 2, or PTT > 60 seconds. Univariate
Poisson regression analysis showed that higher bilirubin
level at VOD diagnosis (P ¼ .01) and greater maximum
deﬁbrotide dose (P ¼ .0003) were associated with bleeding
events.
Thirteen episodes of hypotension were observed in 11
patients. Grades 3 and 4 hypotension accounted for 11 and 2
of the documented episodes, respectively. The onset of hy-
potension occurred at the following doses: 5 at 25 mg/kg/
day (5/100 patient-days), 3 at 25.1 to 59.9 mg/kg/day (1.7/
100 patient-days), 1 at 60 mg/kg/day (0.35/100 patient-
days), 2 at 60.1 to 100 mg/kg/day (1.8/100 patient-days),
and 2 at >100 mg/kg/day (5.3/100 patient-days) (Fisher’s
exact test P ¼ .15).
Six patients had a total of 9 deﬁbrotide dose reductions
(Table 2). Causes for dose reductions were bleeding (n ¼ 4),
severe hypotension (n ¼ 2), coagulopathy (n ¼ 2), and vol-
ume overload (n ¼ 1). Five of the 9 dose reductions occurred
at doses of 110 mg/kg/day. Causes for dose reductions at
110 mg/kg/day were bleeding (3 events), hypotension, and
volume overload. Other nonhematologic adverse events that
occurred on study were infrequent. No death occurred
because of toxicity attributable to deﬁbrotide.
Response and Survival
Complete resolution of VOD occurred in 19 patients
(55.9%; 95% conﬁdence interval, 38% to 73%). Of these 19
patients, 1 received a peak dose of 40 mg/kg/day, 1 received a
peak dose of 52.5 mg/kg/day, 14 received a peak dose of
60 mg/kg/day, 1 received a peak dose of 70 mg/kg/day, 1
received a peak dose of 90 mg/kg/day, and 1 received a peak
dose of 100 mg/kg/day. Of the 11 patients who received a
dose escalation above 60 mg/kg/day, 3 (27%) had resolution
of VOD.
Fifteen patients died of nonrelapse causes within 100 days
of starting deﬁbrotide, giving a 100-day NRM rate of 44% and a
100-day survival rate of 44.1% (95% conﬁdence interval, 30.2%
to 64.4%) (Figure 1). In total, 26 patients died, 9 (35%) due to
relapse/progression and17 (65%) of nonrelapse causes. Twelve
patients (35%) died despite resolution of VOD, 14 (41%) died
without resolution of VOD, and 8 patients (24%) survived a
median of 7 years. Thirteen of 15 patients (87%) with severe
MOF at the time of enrollment died of nonrelapse causes, 10
within 100 days. Eleven of 29 allogeneic transplant recipients
(38%) developed acute graft-versus-host disease, of which 8
(28%) were grades II to IV. Acute graft-versus-host diseasewas
listed as a cause of death in 1 patient and progressed to
extensive chronic graft-versus-host disease in another.
Univariate cumulative incidence and survival analysis
showed that higher peak bilirubin level, receipt of dialysis,
and receipt of mechanical ventilation were all associated
increased NRM and decreased OS (P < .05). Longer time to
Table 2
Deﬁbrotide Exposure, Dosage Reduction, and VOD Response
Patient
No.
Peak
Bilirubin
(mg/dL)
Day of
Peak
Bilirubin
Day of
Deﬁbrotide
Start
Days on
Deﬁbrotide
Peak Dose
(mg/kg/day)
Days at
Peak Dose
No. of
Reductions
(dose)
Reason Result Outcome
Patients who developed VOD post-HCT
1 9.3 52 52 1 <10 1 NR NRM
2 12.5 109 78 3 30 1 NR Disease
3 44.5 65 65 4 37.5 3 NR NRM
4 2.6 3 0 6 40 1 1 (40) Coag CR NRM
5 2.6 14 14 14 52.5 1 CR Alive
6 34.5 43 40 3 60 2 NR NRM
7 5.6 8 8 12 60 4 CR Alive
8 7.1 24 8 30 60 10 1 (60) Coag CR Alive
9 20.5 62 44 7 60 4 NR NRM
10 3.9 6 6 9 60 2 CR NRM
11 7 11 9 13 60 7 CR Alive
12 2.6 8 7 11 60 4 CR Disease
13 11.7 73 58 63 60 39 CR NRM
14 18.1 38 23 16 60 9 NR NRM
15 8.2 21 19 11 60 4 CR Alive
16 5.2 66 63 16 60 8 CR Disease
17 6.1 12 12 32 60 18 CR NRM
18 3.8 34 29 21 60 13 CR Alive
19 5.5 13 13 21 60 8 CR Disease
20 5.5 13 13 26 60 15 CR NRM
21 2.7 8 8 14 60 1 CR Alive
22 13.4 23 10 7 70 4 NR NRM
23 4.1 17 7 37 70 18 CR Alive
24 12 21 19 9 70 1 NR Disease
25 39.8 72 48 26 80 15 NR NRM
26 19.7 35 26 29 90 16 CR Disease
27 4.3 48 40 47 100 5 CR NRM
28 36.6 31 6 42 110 5 2 (110, 90) HT NR NRM
29 38.1 40 25 102 110 7 2 (110, 100) GI NR Disease
30 27.3 39 8 32 110 5 1 (110) MH NR NRM
31 27 68 8 41 110 13 2 (110) AH, VO NR NRM
Patients who developed VOD after chemotherapy
32 40 18 12 7 60 1 NR NRM
33 10.9 12 12 46 60 31 CR Disease
34 25.7 16 7 11 110 4 NR Disease
NR indicates no complete response; NRM, died without relapse; Disease, died with progressive malignancy; CR, complete response; Coag, coagulopathy; HT,
hypotension; GI, gastrointestinal hemorrhage (frank); MH, multisite hemorrhage; AH, alveolar hemorrhage; VO, volume overload.
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associated with NRM. The bilirubin level at the time of VOD
diagnosis and the peak dose of deﬁbrotide was not associ-
ated with either outcome.DISCUSSION
In this prospective single-institution study, deﬁbrotide
was given in escalating doses for the treatment of VOD. Pa-
tients who were not responding at standard doses were
escalated to doses above 60 mg/kg/day. There was no
observed increase in the risk of bleeding until the dose was
greater than 4 times the current standard dose. Of note,Table 3
Bleeding Events on Deﬁbrotide
Dose
(mg/kg/day)
No. of
Patient-
Days
Bleeding
Events
Bleeding Type Bleeding
Events per
100
Patient-Days
25 101 3 2 HU, GI 3
25.1-59.9 175 7 CNS, SH, 2 GI, 2 EX, HU 4
60 286 8 MH, AH, 3 GI, HP, 2 HU 2.8
60.1-100 112 2 BG, GI 1.8
>100 38 5 MH, 2 GI, AH, EX 13.2*
HU indicates hematuria; CNS, intracranial hemorrhage; SH, scleral hemor-
rhage; EX, epistaxis; HP, hemoptysis; BG, bleeding gums.
* P ¼ .008 when compared with all doses 100 mg/kg/day.patients who received deﬁbrotide at 110 mg/kg/day had a
signiﬁcant increase in the incidence of bleeding events. Most
dose reductions due to toxicityalsooccurred at this dose level,
despite only a small fraction of patient-days being spent at
this level. This suggests that deﬁbrotide dosing >100 mg/kg/
day portends a substantial increase in toxicity risk.Figure 1. OS from deﬁbrotide initiation.
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deﬁbrotide, was seen in 11 patients. Five of 13 episodes of
hypotension (38%) occurred at the lowest dose level, and
there was no apparent increase in frequency with increasing
dose. All other signiﬁcant toxicities observed during treat-
ment were those commonly observed in heavily treated,
critically ill, and immunocompromised patients.
Although a randomized trial comparing 25 mg/kg/day
with 40 mg/kg/day showed no beneﬁt at the higher dose
[12], the impact of further dose escalation above 40 mg/kg/
day on survival has not been studied. In this dose escalation
trial, 55.9% of patients achieved resolution of VOD, and the
100-day survival rate was 44.1%. This outcome is similar to
contemporary trials of deﬁbrotide for VOD [13,17,19,22]. This
suggests that escalation to very high doses of deﬁbrotide is
not uniformly more effective than standard dosing. Three of
11 patients with persistent VOD at 60 mg/kg/day responded
when dosing was escalated further, but individual case re-
view showed no evidence that the increase in dosing was
responsible for their response. Although higher doses of
deﬁbrotide may facilitate responses in a subset of patients
who remain refractory at standard doses, a randomized
study is required to properly interrogate this possibility. The
data available thus far from this study and others, however,
do not support routine use of high-dose deﬁbrotide in an
attempt to improve efﬁcacy.
Limitations of this study include the relatively small pa-
tient population and the relatively lowexposure (150patient-
days) at doses above 60mg/kg/day. The lack of randomization
between escalating doses and standard dosing limits con-
clusions regarding the efﬁcacy of this dose escalation
approach. Although at VOD diagnosis there were no differ-
ences between the patients who ultimately received esca-
lated doses of deﬁbrotide and those who did not, a higher
bilirubin level at VOD diagnosis was associatedwith bleeding
in univariate analysis. Although other factors such as peak
bilirubin level, receipt of dialysis, and receipt of mechanical
ventilation were not associated with bleeding events in this
study, the study design may have confounded toxicity ﬁnd-
ings, because patients with poorly responsive VOD were
destined to receive the highest doses of deﬁbrotide.
In conclusion, we found that deﬁbrotide could be safely
escalated to doses well above the current standard without
an increase in bleeding risk in this cohort, and the bleeding
risk at doses up to 100 mg/kg/day in patients with VOD was
approximately 3 bleeding episodes per 100 patient-days of
deﬁbrotide exposure. Although a delay in the initiation of
deﬁbrotide has been associated with worse outcomes
[22,26], some physicians remain reluctant to start deﬁbrotide
therapy because of toxicity concerns. The wide therapeutic
index demonstrated in these patients with severe VOD who
received escalation to high doses of deﬁbrotide indicates that
treatment should not be withheld or delayed because of
concerns of bleeding risk. Of note, a small subset of patients
who were not responding to doses up to 60 mg/kg/day did
attain a response at higher doses. However, the efﬁcacy of
deﬁbrotide at higher doses remains unknown, and doses
above 100 mg/kg/day were associated with a signiﬁcant in-
crease in the risk of bleeding events.ACKNOWLEDGMENTS
The authors thank our colleagues for data collection and
clinical management. Thanks to Dr. David Shook for his
support and advice. The authors also thank the manypatients and families who participated in the transplantation
and cellular therapy research program.
Financial disclosure: Supported in part by the National
Institutes of Health Cancer Center Support (CORE) grant P30
CA021765, National Cancer Institute grant 5 R25 CA23944, a
Center of Excellence Grant from the State of Tennessee, the
Assisi Foundation of Memphis, and the American Lebanese
Syrian Associated Charities.
Conﬂict of interest statement: The authors have no ﬁnan-
cial relationships or other conﬂicts of interest to disclose
relevant to this manuscript.REFERENCES
1. Barker CC, Butzner JD, Anderson RA, et al. Incidence, survival and risk
factors for the development of veno-occlusive disease in pediatric
hematopoietic stem cell transplant recipients. Bone Marrow Transplant.
2003;32:79-87.
2. Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive
disease following stem cell transplantation: incidence, clinical course,
and outcome. Biol Blood Marrow Transplant. 2010;16:157-168.
3. Ho VT, Linden E, Revta C, Richardson PG. Hepatic veno-occlusive
disease after hematopoietic stem cell transplantation: review and up-
date on the use of deﬁbrotide. Semin Thromb Hemost. 2007;33:373-388.
4. Nurnberger W, Michelmann I, Burdach S, Gobel U. Endothelial
dysfunction after bone marrow transplantation: increase of soluble
thrombomodulin and PAI-1 in patients with multiple transplant-
related complications. Ann Hematol. 1998;76:61-65.
5. Wadleigh M, Ho V, Momtaz P, Richardson P. Hepatic veno-occlusive
disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol.
2003;10:451-462.
6. McDonald GB, Sharma P, Matthews DE, et al. Venocclusive disease of
the liver after bone marrow transplantation: diagnosis, incidence, and
predisposing factors. Hepatology. 1984;4:116-122.
7. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the
liver following bone marrow transplantation. Transplantation. 1987;44:
778-783.
8. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the
liver and multiorgan failure after bone marrow transplantation: a
cohort study of 355 patients. Ann Intern Med. 1993;118:255-267.
9. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic
veno-occlusive disease after blood or marrow transplantation: a pro-
spective cohort study of the European Group for Blood and Marrow
Transplantation. EuropeanGroup for Blood andMarrowTransplantation
Chronic Leukemia Working Party. Blood. 1998;92:3599-3604.
10. Bearman SI, Anderson GL, Mori M, et al. Venoocclusive disease of the
liver: development of a model for predicting fatal outcome after
marrow transplantation. J Clin Oncol. 1993;11:1729-1736.
11. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic
venocclusive disease with recombinant human tissue plasminogen
activator and heparin in 42 marrow transplant patients. Blood. 1997;
89:1501-1506.
12. Richardson PG, Soiffer RJ, Antin JH, et al. Deﬁbrotide for the treatment
of severe hepatic veno-occlusive disease and multiorgan failure after
stem cell transplantation: a multicenter, randomized, dose-ﬁnding
trial. Biol Blood Marrow Transplant. 2010;16:1005-1017.
13. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of
deﬁbrotide in 88 patients after stem cell transplantation with severe
veno-occlusive disease and multisystem organ failure: response
without signiﬁcant toxicity in a high-risk population and factors pre-
dictive of outcome. Blood. 2002;100:4337-4343.
14. Kaleelrahman M, Eaton JD, Leeming D, et al. Role of plasminogen
activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated
hepatic veno-occlusive disease and monitoring of subsequent ther-
apy with deﬁbrotide (DF). Hematology. 2003;8:91-95.
15. Richardson PG, Corbacioglu S, Ho VT, et al. Drug safety evaluation of
deﬁbrotide. Exp Opin Drug Saf. 2013;12:123-136.
16. Carreras E, Diaz-Beya M, Rosinol L, et al. The incidence of
veno-occlusive disease following allogeneic hematopoietic stem cell
transplantation has diminished and the outcome improved over the
last decade. Biol Blood Marrow Transplant. 2011;17:1713-1720.
17. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe
veno-occlusive disease with deﬁbrotide: compassionate use results in
response without signiﬁcant toxicity in a high-risk population. Blood.
1998;92:737-744.
18. Corbacioglu S, Kernan N, Lehmann L, et al. Deﬁbrotide for the treat-
ment of hepatic veno-occlusive disease in children after hematopoietic
stem cell transplantation. Exp Rev Hematol. 2012;5:291-302.
19. ChopraR, Eaton JD,Grassi A, et al. Deﬁbrotide for the treatment ofhepatic
veno-occlusive disease: results of the European compassionate-use
study. Br J Haematol. 2000;111:1122-1129.
B.M. Triplett et al. / Biol Blood Marrow Transplant 21 (2015) 2148e2153 215320. Cesaro S, Pillon M, Talenti E, et al. A prospective survey on incidence,
risk factors and therapy of hepatic veno-occlusive disease in children
after hematopoietic stem cell transplantation. Haematologica. 2005;90:
1396-1404.
21. Bulley SR, Strahm B, Doyle J, Dupuis LL. Deﬁbrotide for the treatment of
hepatic veno-occlusive disease in children. Pediatr Blood Cancer. 2007;
48:700-704.
22. Corbacioglu S, Greil J, Peters C, et al. Deﬁbrotide in the treatment of
childrenwith veno-occlusive disease (VOD): a retrospectivemulticentre
study demonstrates therapeutic efﬁcacy upon early intervention. Bone
Marrow Transplant. 2004;33:189-195.23. Gray RJ. A class of K-sample tests for comparing the cumulative inci-
dence of a competing risk. Ann Stat. 1988;16:1141-1154.
24. Prentice RL, Kalbﬂeisch JD, Peterson AV Jr, et al. The analysis of failure
times in the presence of competing risks. Biometrics. 1978;34:541-554.
25. R: A language and environment for statistical computing. R Foundation
for Statistical Computing; Vienna, Austria, 2012.
26. Richardson P, Smith A, Triplett BM, et al. Results of the large pro-
spective study on the use of deﬁbrotide in the treatment of hepatic
veno-occlusive disease in hematopoietic stem cell transplant. early
intervention improves outcomedupdated results of a treatment IND
expanded access protocol. Blood. 2013;122:700.
